Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.79 +2.1%	$0.71	$0.51 ▼ $1.38	$75.63M	0.28	251,887 shs	97,435 shs
CGC Canopy Growth	$1.27 +2.4%	$1.22	$0.77 ▼ $6.30	$304.61M	0.67	22.15 million shs	17.13 million shs
DMAC DiaMedica Therapeutics	$6.11 +3.0%	$4.43	$3.19 ▼ $6.82	$315.82M	1.25	356,804 shs	255,873 shs
OCGN Ocugen	$1.01	$1.03	$0.52 ▼ $1.40	$295.23M	3.84	2.24 million shs	2.29 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	-3.36%	+4.84%	+11.78%	-39.09%
CGC Canopy Growth	0.00%	-2.31%	+14.41%	-30.60%	-80.16%
DMAC DiaMedica Therapeutics	0.00%	+1.33%	+25.20%	+50.49%	+65.14%
OCGN Ocugen	0.00%	-3.81%	-9.82%	+8.51%	-21.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.0191 of 5 stars	3.5	2.0	0.6	0.8	1.3
CGC Canopy Growth	0.7336 of 5 stars	0.0	2.0	3.3	0.8	1.3
DMAC DiaMedica Therapeutics	1.5321 of 5 stars	3.5	0.0	2.4	1.7	0.0
OCGN Ocugen	1.0695 of 5 stars	3.5	2.0	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.38	202.24% Upside
CGC Canopy Growth	1.33	Sell	N/A	N/A
DMAC DiaMedica Therapeutics	3.00	Buy	$12.33	101.85% Upside
OCGN Ocugen	3.00	Buy	$6.00	494.06% Upside

Current Analyst Ratings Breakdown

Latest ASRT, CGC, DMAC, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/12/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
8/12/2025	CGC Canopy Growth	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/4/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/18/2025	DMAC DiaMedica Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $14.00
7/18/2025	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/18/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
6/24/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/24/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$124.96M	0.61	$0.05 per share	16.01	$0.97 per share	0.81
CGC Canopy Growth	$225.65M	1.35	N/A	N/A	$1.47 per share	0.86
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.53 per share	N/A
OCGN Ocugen	$4.05M	72.89	N/A	N/A	$0.01 per share	101.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.45	N/A	26.19	N/A	-36.97%	-38.19%	-15.45%	11/10/2025 (Estimated)
CGC Canopy Growth	-$429.86M	-$3.03	N/A	N/A	N/A	-155.76%	-89.93%	-44.24%	N/A
DMAC DiaMedica Therapeutics	-$24.44M	-$0.69	N/A	N/A	N/A	N/A	-78.99%	-69.94%	11/12/2025 (Estimated)
OCGN Ocugen	-$54.05M	-$0.20	N/A	N/A	N/A	-1,197.71%	-255.25%	-86.79%	N/A

Latest ASRT, CGC, DMAC, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
8/11/2025	Q2 2025	ASRT Assertio	-$0.10	-$0.17	-$0.07	-$0.17	$27.86 million	$29.22 million
8/8/2025	Q1 2026	CGC Canopy Growth	-$0.15	-$0.14	+$0.01	-$0.16	$64.98 million	$52.98 million
8/1/2025	Q2 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	$0.35 million	$1.37 million
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.42	1.59	1.34
CGC Canopy Growth	0.59	3.07	2.12
DMAC DiaMedica Therapeutics	N/A	7.55	7.55
OCGN Ocugen	9.18	1.83	1.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
CGC Canopy Growth	3.33%
DMAC DiaMedica Therapeutics	10.12%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
CGC Canopy Growth	0.16%
DMAC DiaMedica Therapeutics	7.30%
OCGN Ocugen	4.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	96.24 million	92.39 million	Optionable
CGC Canopy Growth	3,150	239.85 million	239.47 million	Optionable
DMAC DiaMedica Therapeutics	20	51.69 million	47.92 million	Optionable
OCGN Ocugen	80	292.30 million	279.39 million	Optionable

ASRT, CGC, DMAC, and OCGN Headlines

Recent News About These Companies

Ocugen reports EMA positive advice for acceptability of OCU410ST

August 13, 2025 | msn.com

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to ...

August 13, 2025 | bakersfield.comB

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

August 13, 2025 | globenewswire.com

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

August 12, 2025 | manilatimes.netM

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

August 12, 2025 | globenewswire.com

Ocugen, Inc. Announces $20 Million Securities Purchase Agreement with Janus Henderson Investors

August 8, 2025 | quiverquant.comQ

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

August 8, 2025 | globenewswire.com

FY2025 EPS Estimates for Ocugen Increased by Chardan Capital

August 8, 2025 | marketbeat.com

HC Wainwright Has Positive Outlook of Ocugen FY2025 Earnings

August 8, 2025 | marketbeat.com

Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital

August 5, 2025 | marketbeat.com

3OCGN : Demystifying Ocugen: Insights From 5 Analyst Reviews

August 4, 2025 | benzinga.com

Ocugen (NASDAQ:OCGN) Posts Earnings Results, Beats Expectations By $0.01 EPS

August 4, 2025 | marketbeat.com

Ocugen, Inc. (NASDAQ:OCGN) Q2 2025 Earnings Call Transcript

August 2, 2025 | msn.com

Ocugen Inc’s Earnings Call: Progress Amid Financial Challenges

August 2, 2025 | msn.com

Ocugen Reports Progress in Gene Therapy Trials

August 1, 2025 | tipranks.com

Ocugen Wins Dismissal of Securities Lawsuit

August 1, 2025 | theglobeandmail.com

Ocugen (OCGN) Q2 Revenue Jumps 20%

August 1, 2025 | fool.com

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

August 1, 2025 | zacks.com

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

August 1, 2025 | globenewswire.com

Ocugen Q2 2025 Earnings Preview

August 1, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, CGC, DMAC, and OCGN Company Descriptions

Assertio NASDAQ:ASRT

$0.79 +0.02 (+2.05%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.78 0.00 (-0.61%)

As of 08/22/2025 07:51 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Canopy Growth NASDAQ:CGC

$1.27 +0.03 (+2.42%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.03 (+2.76%)

As of 08/22/2025 08:00 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

DiaMedica Therapeutics NASDAQ:DMAC

$6.11 +0.18 (+3.04%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.14 +0.03 (+0.56%)

As of 08/22/2025 05:22 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Ocugen NASDAQ:OCGN

$1.01 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.01 +0.00 (+0.50%)

As of 08/22/2025 07:54 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time